Three patients with a muscle-wasting disease died from liver failure after taking the therapy, Ele­vidys, or a similar treatment.

The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the company’s transparency.

The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

The restructuring involves laying off about 500 employees, which is estimated to save $120 million in annual costs in 2026. This year, Sarepta expects to save about $100 million, net of estimated severance charges totaling $32 million to $37 million.